RxDoctor Payments Data

Robert McGowen, MD

Internal Medicine · Wareham, MANPI 1285637405

Payments from drug & device makers

$137in general payments, 2019–2025

Across 8 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$38
  • AstraZeneca$32
  • Nevro Corp.$21
  • Pfizer$18
  • Johnson & Johnson$16
  • Alkermes, Inc.$13

What the payments were for

  • Food & beverage$12692%
  • Education$128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)2$38
AstraZeneca2$32
Nevro Corp.1$21
Pfizer1$18
Johnson & Johnson1$16
Alkermes, Inc.1$13

How this compares

$137 in reported general payments places this provider in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$215,361
Medicare patients
484
Services billed
2,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$100,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$39,557
XareltoRivaroxaban37$36,307
XifaxanRifaximin11$31,586
TrulicityDulaglutide27$28,686
JardianceEmpagliflozin20$26,483
FarxigaDapagliflozin Propanediol29$23,748
OzempicSemaglutide16$18,347
JanuviaSitagliptin Phosphate11$17,595
Breo ElliptaFluticasone/Vilanterol40$15,797
LinzessLinaclotide15$15,269
RybelsusSemaglutide14$15,050
EntrestoSacubitril/Valsartan12$11,614
Spiriva RespimatTiotropium Bromide23$11,399
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$8,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$100,02896 claims
Johnson & JohnsonXarelto$16$36,30737 claims
AstraZenecaFarxiga, Symbicort$32$27,68946 claims
AbbVieLinzess$38$15,26915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Wareham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →